Virtus ETF Advisers’s AstraZeneca AZN Stock Holding History

Virtus ETF Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-306	Closed	-$45K	–	516
2026 Q1	$45K	Buy	+306	New	+$59K	0.02%	396

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Virtus ETF Advisers's AZN Position: Q2 2026 in Review

Virtus ETF Advisers sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 306 shares — an estimated $45K sold.

Virtus ETF Advisers first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $45K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Virtus ETF Advisers reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Virtus ETF Advisers sold 306 AstraZeneca shares in Q2 2026, an estimated $45K.
Virtus ETF Advisers first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
Virtus ETF Advisers's AstraZeneca position peaked at $45K in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.